Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that is primarily used for the management of pain and inflammation associated with various conditions, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. It belongs to the selective cyclooxygenase-2 (COX-2) inhibitor class of medications.
When taken orally, etoricoxib is rapidly absorbed and reaches peak plasma concentrations within 1 to 2 hours. Its bioavailability is approximately 100% when taken with food. The drug is highly bound to plasma proteins, primarily albumin. Etoricoxib is extensively metabolized in the liver, mainly through the CYP3A4 enzyme, with glucuronidation being the major metabolic pathway. The metabolites formed are primarily inactive. The elimination half-life of etoricoxib is around 22 hours.
The recommended dosage of etoricoxib varies depending on the specific condition being treated. It is typically prescribed once daily, and the duration of treatment is determined by the healthcare professional based on the individual patient's response.
Like other NSAIDs, etoricoxib may be associated with certain side effects, including gastrointestinal symptoms and cardiovascular events. It is important to use etoricoxib under the guidance of a healthcare professional and to report any unusual symptoms or adverse reactions promptly.